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Abstract 
Purpose: Brucellosis is a worldwide zoonotic disease and still constitutes a major public 
health problem. In the study we claimed to identify Brucella species from clinical samples of 
patients with active brucellosis from Van region of Eastern Anatolia and to determine in vitro 
antimicrobial susceptibilities of these strains to commonly used anti-Brucella agents and a 
possible new alternative tigecycline. 
Materials and Methods: A total of 56 Brucella isolates were enrolled the study and the 
identification of the isolates were based on conventional methods. In vitro activities of an-
timicrobials were evaluated by the E test method.  
Results: All isolates were identified as B. melitensis. MIC90 values of doxycycline, strepto-
mycin, rifampin, trimethoprim-sulfamethoxazole and tigecycline were 0.064 mg/L, 1 mg/L, 2 
mg/L, 0.125 mg/L and 0.094 mg/L, respectively. Tigecycline had low MIC50 and MIC90 values 
against all B. melitensis strains; the highest MIC observed was 0.25 μg/mL.  
Conclusion: Our data suggest that tigecycline can be a therapeutic alternative option for the 
treatment of brucellosis. 
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Introduction 
Human  brucellosis  remains  the  most  common 
zoonotic disease worldwide, with more than 500,000 
new cases annually [1]. It is caused by Gram-negative 
bacteria, Brucella spp. and is transmissible to humans 
through  direct  contact  with  infected  animals,  con-
sumption of dairy products, or inhalation of aerosols 
[2].  
Brucellosis is a multisystemic disease that shows 
wide clinical polymorphism. Its main clinical signs are 
fever,  headache,  anorexia,  fatigue,  arthritis,  hepato-
splenomegaly, and neurological signs [2]. The disease 
represents serious consequences for public health by 
long  treatment,  slow  recovery  and  possible  serious 
sequelae in the locomotive and nervous  system [2]. 
Although  brucellosis  has  been  eradicated  in  many 
northern European countries, in Australia, New Zea-
land, and Canada due to the implementation of na-
tional surveillance program and vaccination of live-Int. J. Med. Sci. 2011, 8 
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stock,  it  is  still  hyperendemic  in  the  Mediterranean 
basin, Middle East, Southwest Asia and parts of Latin 
America [1,3]. 
In Turkey, brucellosis is common, especially in 
East  and  Southeast  Anatolia  regions  [4,5].  Among 
high-risk patients in the Eastern part of Turkey, se-
ropositivity has been reported to be as high as 27.2% 
[6], but there have been no extensive studies done on 
the identification of Brucella species in this hyperen-
demic part of Anatolia.  
The  genus  Brucella  is  an  intracellular  bacterial 
pathogen that infects host macrophage cells. In con-
sequence, specialized agents that are able to penetrate 
the macrophages and function within their cytoplasm 
are  required  for  the  treatment  of  brucellosis  [2]. 
Therefore, a limited number of antibiotics are effective 
against  these  organisms.  In  1986,  the  WHO  has  re-
leased  recommendations  for  use  of  doxycycline, 
combined  with  either  rifampin  or  streptomycin  for 
treating human brucellosis [7]. Although this recom-
mendation is still in function and Brucella isolates are 
generally considered susceptible to the recommended 
by the WHO antibiotics, sporadic cases of a kind of 
antibiotic resistance have been reported [8,9]. Up until 
2006,  in  vitro  antimicrobial  suspectibility  testing  of 
Brucella  spp  is  not  standardised  and  not  generally 
recommended due to risk of laboratory-acquired in-
fection  and  requirement  of  biological  safety  level  3 
precautions, so there are few studies on this issue in 
the literature [8-16]. Furthermore in vitro susceptibili-
ties  of  these  antibiotics  may  change  over  time  and 
from one geographical region to another [17,18]. 
The  side-effects  of  drug  combination  schemes, 
and  the  high  incidence  of  relapses  and  therapeutic 
failures, have led to the investigation of new drugs to 
treat  the  disease.  Fluoroquinolones,  macrolides  and 
tigecycline (TIG), a member of a new class of antimi-
crobials, the glycylcyclines, may serve as alternative 
drug choices [12-16].  
This study aimed to find the most common Bru-
cella species in this endemic region  of Turkey since 
strategies for disease control and eradication derive 
primarily from the epidemiological characteristics of 
the disease and to determine the in vitro antimicrobial 
susceptibilities  of  these  strains  to  commonly  used 
anti-Brucella  agents  and  a  possible  new  alternative 
tigecycline. 
Materials and Methods  
Bacterial  Strains:  56 Brucella isolates  were col-
lected  prospectively  between  2008-2009  from  blood 
(45),  synovial  fluid  (8),  bone  marrow  (2),  and  cere-
brospinal  fluid  (1)  cultures  of  patients  with  acute 
brucellosis who were admitted to Van Education and 
Research  Hospital  and  the  hospital  of  the  Medical 
Faculty of Van Yuzuncu Yil University (Van, Turkey).  
Identification methods: Identification of species 
was made on the basis of the requirement of CO2 for 
growth, production of urease and H2S, sensitivity to 
the dyes basic fuchsine and thionine (at final concen-
trations  of  20-40  µg/ml),  and  agglutination  with 
monospecific antisera for A and M antigens [19]. The 
strains were stored in skim milk at  –40°C and sub-
cultured twice before the susceptibility tests. 
Antimicrobial susceptibility testing: Minimum 
inhibitory concentration (MIC) of doxycycline (DOX), 
rifampin (RIF), streptomycin (STR), tigecycline (TIG) 
and  trimethoprim-sulfamethoxazole  (TMP-SMZ) 
were  determined  by  E-test  (Biomerieux,  Sweden) 
method on Mueller-Hinton agar (Oxoid, Basingstoke, 
UK) supplemented with 5% sheep blood and inter-
preted  after  48  hours  of  incubation  at  ambient  air. 
Mueller-Hinton agar supplemented with 5% sheep’s 
blood  was  inoculated  with  suspensions  of  the  test 
organism  equivalent  0.5  McFarland  turbidity,  and 
E-test  strips  were  applied  onto  culture  plates.  The 
plates were incubated in ambient air at 35oC and read 
after 48 hours. The MIC was interpreted as the value 
at which the inhibition zone intercepted the scale on 
the E-test strip. MIC50 and MIC90 levels defined as the 
lowest concentration of the antibiotic at  which 50% 
and  90%  of  the  isolates  inhibited,  respectively.  The 
Clinical  Laboratory  Standarts  Institute  (CLSI;  for-
merly  the  NCCLS)  breakpoints  for  TMP-SMZ,  STR, 
DOX  were  employed  for  the  results.  Three  Brucella 
reference strains (B. abortus 544, B. melitensis 16M, and 
B. suis 1330) were used as controls for identification, 
biotyping and antimicrobial susceptibility testing. In 
addition to these Brucella reference strains, Esherichia 
coli ATCC  25922,  Staphylococcus aureus  ATCC  29213 
were also used as the quality control strain for sus-
ceptibility testing. 
Results  
All  isolates  were  identified  as  B.  melitensis.  In 
vitro activities of DOX, STR, RIF, TMP-SMZ, and TIG 
against these isolates were evaluated.  
The MIC values of DOX, STR and TMP-SMZ in-
terpreted according to the CLSI criteria for potential 
bioterrorism agents and interpretive criteria for slow 
growing  bacteria  (Haemophilus)  has  been  used  to 
evaluate the results of MICs of TIG. The MIC50 and 
MIC90 values of relevant antibiotics are shown in Ta-
ble 1. 
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Table 1. MIC range, MIC50 and MIC90 values of antimicrobial agents. 
Antimicrobial  E-test MIC (µg/ml)  CLSI breakpoints (µg/ml) 
MIC ranges  MIC50  MIC90  S   I  R 
DOXa  0.023-0.125  0.047  0.064  ≤ 1  -  - 
TIGb  0.019-0.25  0.064  0.094  NDf     
TMP/SMZc  0.064-0.25  0.064  0.125  ≤ 2  -  - 
STRd  0.064-1.5  1  1  ≤ 8  -  - 
RIFe  0.5-2.0  1.5  2  NDf     
a:Doxycycline; b: Tigecycline; c: Trimethoprim/ sulfamethoxazole (only the trimethoprim portion of the 1/19 drug ratio is displayed); 
d:Streptomycin; e: Rifampin;  
f: not displayed in CLSI table for Brucella spp. 
 
 
 
According  to  MIC90,  DOX  (0.064  µg/ml)  was 
found to be the most active agent, followed by TIG 
(0.094  µg/ml),  TMP-SMZ  (0.125  µg/ml),  STR  (1 
µg/ml) and RIF (2 µg/ml)  respectively. All isolates 
were  found  to  be  sensitive  to  DOX,  STR  and 
TMP-SMZ.  The  MIC  values  of  TIG  interpreted  ac-
cording to the CLSI criteria for slow growing bacteria, 
has shown ranges below the breakpoints for sensitiv-
ity  determination.  The  highest  MIC  of  TIG  against 
Brucella isolates was 0.25µg/ml. 
Discussion 
Brucellosis  is  endemic  in  Turkey  and  approxi-
mately 10,000 cases of human brucellosis are reported 
annually [5]. Brucellosis and its complications are still 
serious  public  health  concern  in  Eastern  Anatolia. 
Although  the  diagnosis  of  brucellosis  can  be  made 
only by the isolation of causative agent; Brucella spp. 
are  difficult  to  isolate  and  the  procedures  are  time 
consuming  and  expensive  [8,20].  Moreover,  Brucella 
spp. are so highly infectious that the attempts at iso-
lation  and  identification  of  Brucella  from  clinical 
specimens  are  not  routinely  performed  [8,20-22]. 
Therefore,  the  epidemiology  of  brucellosis  has  not 
been extensively studied, and limited data are availa-
ble about the prevalence and species most commonly 
encountered in Eastern Anatolia. This is the first study 
which identifies Brucella species and their susceptibil-
ity pattern in this region. Our findings are in accord-
ance with the previous reports from different regions 
of Turkey, Mediterranean and South America basin 
which have revealed that human brucellosis is almost 
exclusively caused by B.melitensis, accounting for 99% 
of total cases [8-16,22-25]. 
In this present study, we also performed in vitro 
susceptibilities of B.melitensis against commonly used 
antimicrobials  and  a  novel  compound  tigecycline. 
Antimicrobial susceptibility testing for Brucella spp is 
not generally recommended for routine microbiology 
laboratories except in life-threatening organ involve-
ment, and in case of treatment failure and relapse [21]. 
Another  problem  with  such  testing  is  the  lack  of 
standardization. Methods for MIC determination are 
described for potential bioterrorism agents including 
Brucella species by the CLSI. The CLSI proposes the 
microbroth dilution method using Brucella broth for 
Brucella spp. The breakpoints used for interpretation 
as susceptible were as follows: TET/DOX ≤1 μg/ml, 
TMP-SMZ ≤2 μg/ml, and STR ≤8 μg/ml according to 
the the CLSI interpretive criteria [26]. In vitro efficacy 
of  antibiotics  against  Brucella  spp.  has  usually  been 
based on the determination of MIC values by micro 
broth dilution, agar dilution, and E-test methods [20]. 
E-test method was found to be reliable, reproducible, 
less  labor-intensive,  less  time-consuming,  and  more 
practical  than  the  broth  micro  dilution  method 
[11,24,27]. Therefore E-test method was used in this 
study.  E-test  could  be  performed  on  two  different 
culture media: the Mueller-Hinton agar plates widely 
used for antibiotic susceptibility testing and the Bru-
cella agar plates commonly used in the laboratory as 
Brucella  growth  medium.  Although  no  significant 
differences were observed between two culture me-
dia,  we  preferred  the  Mueller-Hinton  agar  plate  in 
this study because clearer inhibition zones are visible 
and the calibrated carrier strip indicating the MIC can 
be more easily read [25].  
TET and its derivatives are among the most ef-
fective drugs against brucellosis [2]. DOX has become 
the most commonly prescribed tetracycline derivative 
in the treatment of brucella infections because of its 
superior pharmacokinetic features [28]. In the present 
study,  among  the  tested  antibacterial  agents,  DOX 
was found to have the lowest MIC50 and MIC90 values 
which  is  consistent  with  previous  reports 
[8,10,11,22-24,27,29]. Conversely in a Mexican study, 
Lopez-Merino  et  al.  found  the  MIC  values  for  TET 
were higher than in Brucella strains isolated in Turkey 
[9]  which  demonstrates  the  antibiotic  susceptibility Int. J. Med. Sci. 2011, 8 
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patterns of Brucella strains appear to vary geograph-
ically.  
Another drug of choice in the treatment regimen 
of brucellosis is RIF and it was found to be the only 
antibiotic  with  increased  activity  in  acidic  environ-
mental conditions [27]. In our study, the highest MIC 
values were determined for RIF among the studied 
antimicrobials.  As  MIC  values  of  RIF  in  previous 
studies were reported to range from 0.047 to 4 μg/ml, 
its  values  confirmed  again  by  our  findings 
[8,10-12,22-25]. Memish et al. reported an in vitro re-
sistance  rate  of  3.5%  for  RIF  [31].  These  findings 
should be taken into consideration for the potential 
emergence  of  RIF  resistance  of  Brucella  spp.  in  the 
region. Another concern for RIF using widespread in 
the  long  treatment  regimens  like  brucellosis  may 
cause an increase in RIF resistance in M. tuberculosis 
because both brucellosis and tuberculosis can simul-
taneously exist in the same countries in many parts of 
the  world  [32].  Furthermore  experimental  studies 
suggested that the development of mycobacterial re-
sistance to RIF may lead to development of resistance 
to other antimicrobials as well [32]. The resistance rate 
of RIF against M. tuberculosis was reported as 15–58% 
in Turkey [33]. The burden of such resistance for pub-
lic health must be considered. 
TMP-SMZ containing regimens is considered to 
be suitable oral regimens that may be of significantly 
lower  cost  than  traditional  combinations  in  certain 
developing countries and  mostly prescribed in bru-
cellosis for children and pregnant women [2]. In our 
study  MIC50 and  MIC90  values  for  TMP-SMZ  were 
lower  than  those  previously  observed  in  Turkey 
[8,10,11] and conforming the results of Kilic et al. [16]. 
In vitro TMP-SMZ resistance rate was reported 2% in 
Turkey [8]. However, significant rates of TMP-SMZ 
resistance have been reported in the world [31,34].  
Although streptomycin is known to be one of the 
most active agent against brucellosis, its adverse ef-
fects, such as ototoxicity, nephrotoxicity, and paren-
teral administration, preclude its wider use [24,29]. In 
our study susceptibility to STR was found to be in the 
range described previously [8,10,12,24,29].  
This is one of the few studies which, determines 
the in vitro activity of TIG, a new glycylcycline com-
pound,  against  Brucella strains.  We  found  that  TIG 
was more effective than RIF, TMP-SMZ and STR but 
was not as effective as DOX. Dizbay et al. reported TIG 
was more effective than RIF, SXT, STR, and DOX [8]. 
Also Kilic et al. found TIG had the least MIC50 and 
MIC90 values compared to TET, and fluoroquinolones 
against  Brucella  strains  isolated  in  Central  Anatolia 
[13]. These are in contrast with our findings and might 
be due to the strain specific susceptibility. As MIC50 
and MIC90 values of TIG in these two previous studies 
were  reported  to  be  0.064  and  0.125  μg/ml  respec-
tively, values of them confirmed again by our find-
ings.  
Although TIG has similar properties to TET, it 
has  been  reported  that  it  is  more  potent  than  TET 
[35,36]. TET is the mainstay of anti-brucellosis regi-
men.  Therefore,  Pappas  et  al.  suggested  replacing 
DOX  with  more  potent  TIG  might  increase  efficacy 
and  reduce  treatment  duration  [37].  On  the  other 
hand, parenteral administration of TIG, the conserva-
tion of TIG because of promising results of its use in 
the  treatment  of  multiresistant  bacterial  infections, 
and  overall  cost  were  considered  as  limitations  of 
such a therapy [12].  
In conclusion, there is no significantly important 
resistance problem for classically recommended anti-
biotics targeted to Brucella species in Turkey, but an-
tibiotic susceptibility patterns of Brucella spp. appear 
to  vary  geographically.  Therefore,  we  suggest,  re-
gional periodic assessment of susceptibility of strains 
to  antimicrobials.  The  results  of  this  in  vitro  study 
suggest TIG as a therapeutic option in the treatment of 
brucellosis. Clinical trials are warranted to assess the 
real therapeutic potential of TIG in human brucellosis, 
particularly  in  countries  with  higher  prevalence  of 
antibiotic resistance. 
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